Search

Your search keyword '"Kok, Yonatan"' showing total 11 results
Start Over Author "Kok, Yonatan"
11 results on '"Kok, Yonatan"'

1. Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients

Author

Allen, Nicholas C., primary, Martin, Andrew J., additional, Snaidr, Victoria A., additional, Eggins, Renee, additional, Chong, Alvin H., additional, Fernandéz-Peñas, Pablo, additional, Gin, Douglas, additional, Sidhu, Shireen, additional, Paddon, Vanessa L., additional, Banney, Leith A., additional, Lim, Adrian, additional, Upjohn, Edward, additional, Schaider, Helmut, additional, Ganhewa, Aparna D., additional, Nguyen, Jennifer, additional, McKenzie, Catriona A., additional, Prakash, Saurabh, additional, McLean, Catriona, additional, Lochhead, Alistair, additional, Ibbetson, Jan, additional, Dettrick, Andrew, additional, Landgren, Anthony, additional, Allnutt, Katherine J., additional, Allison, Clare, additional, Davenport, Rachael B., additional, Mumford, Blake P., additional, Wong, Brittany, additional, Stagg, Brendan, additional, Tedman, Alexander, additional, Gribbin, Hannah, additional, Edwards, Harrison A., additional, De Rosa, Nicholas, additional, Stewart, Thomas, additional, Doolan, Brent J., additional, Kok, Yonatan, additional, Simpson, Kate, additional, Low, Zhi M., additional, Kovitwanichkanont, Tom, additional, Scolyer, Richard A., additional, Dhillon, Haryana M., additional, Vardy, Janette L., additional, Chadban, Steven J., additional, Bowen, David G., additional, Chen, Andrew C., additional, and Damian, Diona L., additional

Published
2023
Full Text
View/download PDF

2. Improving Skin cancer Management with ARTificial Intelligence (SMARTI): a pre-post intervention trial of an Artificial Intelligence system used as a diagnostic aid for skin cancer management in a real-world specialist dermatology setting

Author

Felmingham, Claire, primary, Pan, Yan, additional, Kok, Yonatan, additional, Kelly, John, additional, Gin, Douglas, additional, Nguyen, Jennifer, additional, Goh, Michelle, additional, Chamberlain, Alex, additional, Oakley, Amanda, additional, Tucker, Simon, additional, Berry, William, additional, Darling, Mark, additional, Jobson, Dale, additional, Robinson, Aaron, additional, de Menezes, Sara, additional, Wang, Charlie, additional, Willems, Anneliese, additional, McLean, Catriona, additional, Cranwell, William, additional, Adler, Nikki, additional, Wada, Miki, additional, Foley, Peter, additional, Brack, Jane, additional, Cumming, Simon, additional, Byars, Gabrielle, additional, Bowling, Adrian, additional, Ge, Zongyuan, additional, Haskett, Martin, additional, Wolfe, Rory, additional, and Mar, Victoria, additional

Published
2022
Full Text
View/download PDF

3. Improving skin cancer management with ARTificial intelligence: A pre-post intervention trial of an artificial intelligence system used as a diagnostic aid for skin cancer management in a real-world specialist dermatology setting.

Author

Felmingham, Claire, Pan, Yan, Kok, Yonatan, Kelly, John, Gin, Douglas, Nguyen, Jennifer, Goh, Michelle, Chamberlain, Alex, Oakley, Amanda, Tucker, Simon, Berry, William, Darling, Mark, Jobson, Dale, Robinson, Aaron, de Menezes, Sara, Wang, Charlie, Willems, Anneliese, McLean, Catriona, Cranwell, William, and Adler, Nikki

Published
2023
Full Text
View/download PDF

11. Assessing quality of life and depression in psoriasis patients: A cross‐sectional study.

Author

Kok, Yonatan, Braue, Anna, Martyres, Raymond, and Varigos, George

Subjects
*CROSS-sectional method, *QUALITY of life, *PSORIASIS
Abstract

Assessing quality of life and depression in psoriasis patients: A cross-sectional study Psoriasis is a chronic, auto-immune skin condition with a severe impact on mental health and marked quality-of-life impairment due to its effect on cosmesis and physical function.[[1]] Depression is common in psoriasis patients with an estimated prevalence rate of 30%.[1] It has been shown to account for the significant portion of quality impairment in the Dermatology Life Quality Index (DLQI) that could not otherwise be explained by the low Psoriasis Area Severity Index (PASI).[[3]] A literature review has recently shown that the DLQI has major weaknesses in reporting the mental and emotional aspects of quality of life.[5] The Beck Depression Inventory-II (BDI-II) is a clinical instrument commonly used in psychiatry to screen for depression, but its use is not currently a standard practice in dermatology.[6] This letter analyses the DLQI's ability to detect depression in psoriasis patients and evaluates the association between the domains of quality of life in the DLQI and depression. The evidence presented here suggests that whilst quality of life, disease severity and depression are linked, both the PASI and DLQI have a low sensitivity for detecting clinical depression in psoriasis patients. [Extracted from the article]

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results